March 14th, 2009
Sedating HIV-Infected Endoscopy Patients
In a recent blog post, ID expert Paul Sax raised the question of which sedatives should be used when scoping HIV-infected patients on ritonavir or efavirenz. Both antiretrovirals inhibit the CYP3A enzyme, which metabolizes one of our most commonly used sedatives, midazolam. Use of midazolam with either antiretroviral is technically contraindicated because of significant increases that occur in blood levels of midazolam. So how do we sedate our HIV-infected colonoscopy patients?
The same as we do all our endoscopy patients: We titrate midazolam for effect. In my mind, there is little reason to view this drug as “contraindicated” with ritonavir or efavirenz. Increased blood levels of midazolam should lead to adequate sedation at lower doses without the potential for over-sedation, assuming the midazolam is used appropriately — that is, infused at a low dose with a reassessment of effect and level of sedation before additional doses are given.
However, Paul noted in his blog that lorazepam (Ativan) and other drugs are sometimes substituted for midazolam in this situation or that the patient’s ritonavir is stopped the day before midazolam is used. Frankly, the mention of these practices surprised me and led me to conduct this informal poll…
What do you do when you encounter these patients?
Categories: Endoscopy, Patient care
Tags: antiretroviral therapy, colonoscopy, efavirenz, HIV, midazolam, ritonavir, sedation
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
2 Responses to “Sedating HIV-Infected Endoscopy Patients”
M. Brian Fennerty, MD
Founding Editor
NEJM Journal Watch Gastroenterology
Learn more about Gut Check on Gastroenterology.
Pages
Archives
- October 2014
- August 2014
- July 2014
- June 2014
- March 2014
- January 2014
- December 2013
- November 2013
- September 2013
- August 2013
- July 2013
- June 2013
- April 2013
- February 2013
- December 2012
- November 2012
- October 2012
- August 2012
- July 2012
- April 2012
- February 2012
- January 2012
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- October 2010
- August 2010
- July 2010
- March 2010
- February 2010
- January 2010
- December 2009
- July 2009
- June 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
Categories
- Barrett esophagus (1)
- cancer surveillance (4)
- colonoscopy (4)
- drugs (1)
- Endoscopy (23)
- eosinophilic esophagitis (1)
- gastric acid suppression (1)
- Health policy (3)
- Hepatology (3)
- Medical education (1)
- pathology (1)
- Patient care (28)
- polypectomy (2)
- practice environment (3)
- Probiotic therapy (1)
- Ulcer (1)
- Uncategorized (30)
-
Tag Cloud
- Ambulatory endoscopy center antiretroviral therapy Barrett esophagus boceprevir bowel preparation CMS colitis colonoscopy colorectal cancer screening CT colonography DDW drug interactions efavirenz endoscopist Endoscopy gastroenterology GI bleeding hepatitis HIV IBS Irritable Bowel Syndrome Medicare midazolam nurse Plavix PPIs primary care probiotics ritonavir Screening colonoscopy sedation sigmoidoscopy telaprevir training virtual colonoscopy
Brian, thanks for getting this issue out there to your GI colleagues. We have a meeting with the group in charge of policy on “conscious sedation,” and this specific question will be discussed — hope to get it resolved.
Just for the record, our HIV patients now have a projected life expectancy estimated to be decades — cancer screening recommendations that apply to HIV negative patients apply equally to them. Furthermore, the vast majority of HIV patients on antiviral therapy are receiving either efavirenz or ritonavir, so this issue of sedation for colonoscopies is a highly relevant question.
Propofol